| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Hospices Civils de Lyon |
| Information provided by: | Hospices Civils de Lyon |
| ClinicalTrials.gov Identifier: | NCT00169598 |
Purpose
This randomised study aimed at evaluating the medical and economical impact of positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) in the therapeutic prescription in patients with Hodgkin’s lymphoma or with large B and P cell non-Hodgkin’s lymphoma. The median progression free survival, the costs and the quality of life are compared between two groups : Group 1: the results of conventional staging and of the PET are known before stem cell transplantation. Group 2: only the results of conventional staging before stem cell transplantation are known before stem cell transplantation.
| Condition | Intervention |
|
Lymphoma |
Procedure: positron emission tomography |
| MedlinePlus related topics: | CT Scans Lymphoma |
| ChemIDplus related topics: | Deoxyglucose |
| Study Type: | Interventional |
| Study Design: | Diagnostic, Randomized, Open Label, Uncontrolled, Parallel Assignment |
| Official Title: | Remission Evaluation Before Intensified Treatment in Lymphoma: Impact of Positron Emission Tomography (PET) Using Fluorine-18-Floro-Deoxyglucose (FDG) in the Therapeutic Prescription. Medico-Economic Randomised Study |
| Estimated Enrollment: | 80 |
| Study Start Date: | February 2002 |
Eligibility
| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Age over 18, with Hodgkin’s lymphoma or with large B and P cell non-Hodgkin’s lymphoma, or after a first-line chemotherapy with at least a residual mass or after induction chemotherapy or at progression.
Stem cell transplantation would be programmed. Patients were required to give their written informed consent.
Exclusion Criteria:
Progressive cancer or diagnosed less than 5 years, except cancer in situ of the cervix and basocell skin carcinoma, kidney insufficiency or diabetes. Patients would not be pregnant or lactating
Contacts and Locations More Information
| Study ID Numbers: | 2000.232 |
| First Received: | September 13, 2005 |
| Last Updated: | April 26, 2007 |
| ClinicalTrials.gov Identifier: | NCT00169598 |
| Health Authority: | France: Afssaps - French Health Products Safety Agency |
|
|
|
|
|
